GRAIL, Inc.
Business
GRAIL, Inc. develops Galleri, a multi-cancer early detection blood test that screens asymptomatic individuals for over 50 cancer types from a single draw. The test identifies cancer signals and predicts cancer origin. GRAIL operates a CAP-accredited, CLIA-certified laboratory using proprietary targeted methylation technology. The company distributes tests through partnerships with healthcare systems, employers, payors, and digital health platforms, and has submitted a premarket approval application to the FDA.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Total revenue | 147 | 126 | 93 | 56 | |
| Cost of revenue amortization of intangible assets | 134 | 134 | 134 | — | |
| Research and development | 196 | 322 | 339 | 330 | |
| Sales and marketing | 117 | 154 | 162 | 122 | |
| General and administrative | 159 | 214 | 200 | 174 | |
| Goodwill and intangible assets impairment | 28 | 1,421 | 718 | 4,700 | |
| Total costs and operating expenses | 709 | 2,315 | 1,608 | 5,498 | |
| Loss from operations | −562 | −2,189 | −1,515 | −5,443 | |
| Interest income | 29 | 27 | 8 | 2 | |
| Other income (expense), net | −993,000 | 64,000 | −208,000 | −238,000 | |
| Total other income, net | 28 | 27 | 8 | 2 | |
| Loss before income taxes | −535 | −2,162 | −1,508 | −5,441 | |
| Benefit from income taxes | 126 | 135 | 42 | 42 | |
| Net loss | −408 | −2,027 | −1,466 | −5,399 | |
| Net loss per share Basic (in dollars per share) | −11.11 | −63.54 | −47.21 | −173.89 | |
| Net loss per shareDiluted (in dollars per share) | −11.11 | −63.54 | −47.21 | −173.89 | |
| Weighted-average shares of common stock used in computing net loss per sharebasic (in shares) | 37 | 32 | 31 | 31 | |
| Weighted-average shares of common stock used in computing net loss per sharediluted (in shares) | 37 | 32 | 31 | 31 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 250 | 214 | 97 | 242 | |
| Short-term marketable securities | 655 | 549 | 0 | — | |
| Accounts receivable, net | 18 | 20 | 17 | — | |
| Supplies | 16 | 19 | 22 | — | |
| Prepaid expenses and other current assets | 15 | 17 | 20 | — | |
| Total current assets | 954 | 820 | 156 | — | |
| Property and equipment, net | 52 | 69 | 85 | — | |
| Operating lease right-of-use assets | 52 | 66 | 84 | — | |
| Restricted cash | 7 | 3 | 4 | — | |
| Intangible assets, net | 1,900 | 2,017 | 2,687 | — | |
| Other non-current assets | 7 | 8 | 8 | — | |
| Total assets | 2,922 | 2,983 | 3,914 | — | |
| Accounts payable | 2 | 5 | 20 | — | |
| Accrued liabilities | 64 | 57 | 74 | — | |
| Operating lease liabilities, current portion | 12 | 13 | 15 | — | |
| Other current liabilities | 2 | 2 | 809,000 | — | |
| Total current liabilities | 80 | 77 | 164 | — | |
| Operating lease liabilities, net of current portion | 43 | 55 | 70 | — | |
| Deferred tax liability, net | 219 | 346 | 33 | — | |
| Other non-current liabilities | 3 | 2 | 1 | — | |
| Total liabilities | 344 | 480 | 268 | — | |
| Commitments and contingencies (Note 10) | — | — | — | — | |
| Preferred stock, par value of $0.001 per share; 50,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | |
| Common stock $0.001 par value per share, 1,500,000,000 shares authorized, 40,331,360 and 33,893,409 shares issued and outstanding as of December 31, 2025 and December 31, 2024. | 40,000 | 34,000 | — | — | |
| Additional paid-in capital | 12,787 | 12,305 | — | — | |
| Accumulated other comprehensive income | 3 | 1 | 1 | — | |
| Accumulated deficit | −10,212 | −9,803 | −7,776 | — | |
| Total stockholders equity | 2,578 | 2,503 | — | — | |
| Total liabilities and stockholders equity | 2,922 | 2,983 | 3,914 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Amortization of intangibles assets | 138 | 138 | 138 | — | |
| Depreciation | 18 | 20 | 20 | 16 | |
| Stock-based compensation expense | 58 | 86 | 97 | 76 | |
| Deferred income taxes | −126 | −134 | −38 | −39 | |
| Amortization of discount on marketable securities | −21 | −3 | 0 | 0 | |
| Credit loss expense | 332,000 | 0 | 0 | — | |
| Cash payment for equity awards | 0 | −54 | −77 | −41 | |
| Other | 1 | 276,000 | 3 | 1 | |
| Accounts receivable | 2 | −3 | −1 | −9 | |
| Supplies | 3 | 3 | −2 | −14 | |
| Operating lease right-of-use assets and liabilities, net | 1 | 2 | 7 | 5 | |
| Prepaid expenses and other assets | 3 | 2 | −908,000 | −11 | |
| Accounts payable | −3 | −15 | 3 | 2 | |
| Accrued and other liabilities | 6 | −13 | 2 | 12 | |
| Net cash used by operating activities | −299 | −577 | −596 | −561 | |
| Purchases of property and equipment | −909,000 | −5 | −13 | −23 | |
| Purchases of marketable securities | −1,308 | −546 | 0 | 0 | |
| Proceeds from maturities of marketable securities | 1,224 | 0 | 0 | — | |
| Net cash used in investing activities | −85 | −551 | −13 | −23 | |
| Issuance of common stock under ESPP | 5 | 0 | 0 | — | |
| Cash funding received from Illumina | 0 | 1,244 | 464 | 609 | |
| Other | 0 | 0 | −234,000 | −4 | |
| Net cash provided by financing activities | 423 | 1,244 | 464 | 605 | |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | −147,000 | −62,000 | 305,000 | −511,000 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 39 | 116 | −145 | 20 | |
| Property and equipment included in accounts payable and accrued liabilities | −42,000 | 0 | −1 | −2 | |
| Operating cash flows from operating leases, net | −17 | −19 | −19 | −18 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GRAIL, Inc.'s CIK number?
GRAIL, Inc.'s SEC CIK number is 0001699031 (1699031). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GRAIL, Inc.'s SEC filings?
All of GRAIL, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did GRAIL, Inc. last report earnings?
GRAIL, Inc. (GRAL) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-030495). This is GRAIL, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is GRAIL, Inc.'s most recent earnings 8-K?
GRAIL, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001628280-26-030495. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View GRAIL, Inc.'s latest earnings 8-K →
Look up any company's CIK number →